Cytoguide Overview
- Year Founded
-
2007
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Cytoguide General Information
Description
Developer of combined drugs that target receptors on cells in pathological tissues. The company offers drugs that are aimed to improve the treatment of onocyte and macrophage-related diseases including autoimmune disease, leukemia and other infectious diseases.
Contact Information
Website
cytoguide.dkCorporate Office
- INCUBA Science Park
- Gustav Wieds Vej 10
- 8200 Aarhus
- Denmark
Corporate Office
- INCUBA Science Park
- Gustav Wieds Vej 10
- 8200 Aarhus
- Denmark
Cytoguide Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 01-Oct-2013 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 08-Dec-2010 | Completed | Startup | |||
| 3. Early Stage VC | 02-Jun-2009 | Completed | Startup | |||
| 2. Early Stage VC | 28-Nov-2008 | $2.39M | $2.68M | Completed | Startup | |
| 1. Seed Round | 01-Nov-2007 | $287K | $287K | Completed | Startup |
Cytoguide Patents
Cytoguide Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2013093465-A3 | Formulations | Inactive | 23-Dec-2011 | ||
| WO-2013093465-A2 | Novel formulations | Inactive | 23-Dec-2011 | ||
| US-20020155995-A1 | Haptoglobin-haemoglobin complex or a part thereof or a mimic thereof being operably linked to a substance; capable of binding a cd163 receptor and/or a cd163 receptor variant. | Inactive | 22-Feb-2001 | ||
| US-20050063951-A1 | Haptoglobin-hemoglobin (hp-hb) complex capable of binding a cd163 receptor, conjugated to another active agent such as an antimicrobial agent, an anticancer drug, an anti-hiv drug; gene therapy of sickle cell anemia for example | Inactive | 22-Feb-2001 | ||
| DE-60140069-D1 | Function of a haptoglobin hemoglobin receptor and application therefor | Inactive | 16-Oct-2000 | G01N33/721 |
Cytoguide Former Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Capnova | Venture Capital | Minority | ||
| KDventures | Venture Capital | Minority | ||
| Lund University Bioscience | Venture Capital | Minority | ||
| Novo Holdings | Venture Capital | Minority |
Cytoguide FAQs
-
When was Cytoguide founded?
Cytoguide was founded in 2007.
-
Where is Cytoguide headquartered?
Cytoguide is headquartered in Aarhus, Denmark.
-
What industry is Cytoguide in?
Cytoguide’s primary industry is Drug Discovery.
-
Is Cytoguide a private or public company?
Cytoguide is a Private company.
-
What is Cytoguide’s current revenue?
The current revenue for Cytoguide is .
-
How much funding has Cytoguide raised over time?
Cytoguide has raised $2.68M.
-
Who are Cytoguide’s investors?
Capnova, KDventures, Lund University Bioscience, and Novo Holdings have invested in Cytoguide.
-
When was Cytoguide acquired?
Cytoguide was acquired on 01-Oct-2013.
-
Who acquired Cytoguide?
Cytoguide was acquired by Affinicon.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process